"Preliminary estimates released by the Centers for Disease Control and Prevention indicate that the number of Americans diagnosed with Lyme disease each year is around 300,000. The preliminary estimates were presented Sunday night in Boston at "...
Hyalgan® (hyaluronate) was investigated in a pivotal clinical investigation conducted in the United States in which there were three arms (164 subjects treated with Hyalgan® (hyaluronate) ; 168 with placebo; and 163 with naproxen) (refer to Table 1).
Incidence1 of Adverse Events Occuring in More Than 5% of All Subjects
|Adverse Event|| Hyalgan®
|Gastrointestinal complaints2||48 (29%)||59 (36%)|
|Injection site pain3||38 (23%)4||22 (13%)|
|Headache||30 (18%)||29 (17%)|
|Local skin5||23 (14%)||17 (10%)|
|Local joint pain and swelling6||21 (13%)||22 (13%)|
|Pruritus (local)||12 (7%)||7 (4%)|
1 Notes: Number and % of subjects
2 Severe in 4 Hyalgan® (hyaluronate) -treated subjects and 4 placebo-treated subjects
3 Severe in 5 Hyalgan® (hyaluronate) -treated subjects and 2 placebo-treated subjects
4 Statistically significant (p=0.02)
5 Includes ecchymosis and rash
6 Severe in 2 Hyalgan® (hyaluronate) -treated subjects (1.2%) and 1 placebo-treated subject
Common adverse events reported for the Hyalgan® (hyaluronate) -treated subjects were gastrointestinal complaints, injection site pain, knee swelling/effusion, local skin reactions (rash, ecchymosis), pruritus, and headache. Swelling and effusion, local skin reactions (ecchymosis and rash), and headache occurred at equal frequency in the Hyalgan® (hyaluronate) and placebo-treated groups. Hyalgan® (hyaluronate) -treated subjects had 48/164 (29%) incidents of gastrointestinal complaints that were not statistically different from the placebo-treated group. A statistically significant difference in the occurrence of pain at the injection site was noted in the Hyalgan® (hyaluronate) -treated subjects; 38/164 (23%) in comparison to 22/168 (13%) in the placebo-treated subjects (p=0.022). There were 6/164 (4%) premature discontinuations in Hyalgan® (hyaluronate) -treated subjects due to injection site pain in comparison to 1/168 ( < 1%) in the placebo-treated subjects. These differences were not statistically significant.
Two (2/164, 1.2%) Hyalgan® (hyaluronate) -treated subjects and 3/168 (1.8%) placebo-treated subjects were reported to have positive bacterial cultures of effusion aspirated from the treated knee. The two Hyalgan® (hyaluronate) -treated subjects and two of the placebo-treated subjects did not exhibit evidence of infection clinically or subsequently and were not treated with antibiotics. One of the placebo-treated subjects was hospitalized and received presumptive treatment for septic arthritis.
Hyalgan® (hyaluronate) has been in clinical use in Europe since 1987. Analysis of the adverse events that have been reported with the use of Hyalgan® (hyaluronate) in Europe reveals that most of the events are related to local symptoms such as pain, swelling/effusion, and warmth or redness at the injection site. In the two events reported as anaphylactoid reactions, Hyalgan® (hyaluronate) treatment was discontinued and both had favorable outcomes. Three cases of allergic reactions were reported in which the patients were discontinued from Hyalgan® (hyaluronate) treatment and the incidents resolved. Seven cases of fever were reported in which three of the cases were reported to be associated with local reactions; pyogenic arthritis was reported to be ruled out in these three cases. All the fever patients were discontinued from Hyalgan® (hyaluronate) treatment and all incidents resolved. One incident of shock (which was described as a "hypotensive crisis") was reported. The incident resolved and Hyalgan® (hyaluronate) treatment was continued.
Adverse experience data from the literature contain no evidence of increased risk relating to retreatment with Hyalgan® (hyaluronate) . The frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle. (Carrabba et al., 1995; Carrabba et al., 1991; Kotz and Kolarz, 1999; Scali, 1995).
Read the Hyalgan (hyaluronate) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 12/15/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Hyalgan Information
Hyalgan - User Reviews
Hyalgan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options